Loading
Immunotherapy and Immune Responses · Journal article
Medicina · August 18, 2026
Encouraging direction, but not yet definitive.
In this retrospective cohort of 139 stage IV NSCLC patients receiving first-line ICI therapy, COVID-19 vaccination was associated with longer median PFS (13.0 vs. 11.0 months) and OS (29.0 vs. 24.0 months) in unadjusted analysis, with a dose-related pattern favouring ≥2 doses. However, in multivariable models adjusted for tumour biology and other factors, the survival benefit was substantially attenuated and reached only borderline significance (OS HR 0.83, 95% CI 0.69–0.99), suggesting confounding by unmeasured prognostic factors.
Retrospective cohort study. Patients with stage IV non-small cell lung cancer treated with first-line immune checkpoint inhibitor-based therapy, stratified by vaccination status.. Intervention: COVID-19 vaccination (0–1 or ≥2 doses) concurrent with first-line ICI therapy for stage IV NSCLC.. Compared with: No vaccination or 0–1 doses vs. ≥2 doses; stratified analysis.. n = 139. Romania.
Vaccinated patients: median PFS 13.0 vs. 11.0 months (p < 0.001); median OS 29.0 vs. 24.0 months (p < 0.001) in unadjusted analysis. Patients receiving ≥2 vaccine doses: median PFS 14.0 vs. 12.0 months (p = 0.001); median OS 30.0 vs. 24.0 months (p < 0.001). Multivariable OS: HR = 0.83 (95% CI 0.69–0.99); multivariable PFS: HR = 0.79 (95% CI 0.62–0.99), both borderline.
Exploratory toxicity analysis; no comparison of treatment response rates or immune-related adverse events between groups reported. Higher odds of any-grade toxicity with ≥2 doses: OR = 2.47 (p = 0.037); predominantly low grade, no Grade 4–5 toxicity reported.
While the unadjusted survival benefit associated with COVID-19 vaccination is substantial, clinicians should note that the effect was attenuated to borderline significance after adjustment for tumour biology and other factors. This suggests that vaccination safety is supported but the clinical benefit remains hypothesis-generating and requires prospective validation before informing treatment decisions in this population.
A real observational finding of improved survival with COVID-19 vaccination in advanced NSCLC on immunotherapy, but confounded by unmeasured factors and attenuated to borderline significance in multivariable analysis; requires prospective validation.
As stated by the source record.
Quoted from the source exactly as published.
While the unadjusted survival benefit associated with COVID-19 vaccination is substantial, clinicians should note that the effect was attenuated to borderline significance after adjustment for tumour biology and other factors. This suggests that vaccination safety is supported but the clinical benefit remains hypothesis-generating and requires prospective validation before informing treatment decisions in this population.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background: The interaction between COVID-19 vaccination and immune checkpoint inhibitor (ICI) therapy in advanced non-small cell lung cancer (NSCLC) remains incompletely characterized. Methods: Retrospective cohort study of 139 patients with stage IV NSCLC treated with first-line ICI-based therapy, stratified by vaccination status and total doses received (0–1 vs. ≥2). Progression-free (PFS) and overall survival (OS) were analyzed by Kaplan–Meier and Cox regression; logistic regression explored factors associated with treatment-related toxicity. Results: Vaccinated patients had longer median PFS (13.0 vs. 11.0 months) and OS (29.0 vs. 24.0 months; both p < 0.001). In multivariable models these associations were attenuated and of borderline significance (OS HR = 0.83, 95% CI 0.69–0.99; PFS HR = 0.79, 95% CI 0.62–0.99). Outcomes were also more favorable with ≥2 doses (median PFS 14.0 vs. 12.0 months, p = 0.001; median OS 30.0 vs. 24.0 months, p < 0.001), and tumor mutational status was the strongest independent predictor of survival. In an exploratory model, ≥2 doses were associated with higher odds of any-grade toxicity (OR = 2.47, p = 0.037); events were predominantly low grade, with no Grade 4 or 5 toxicity. Conclusions: COVID-19 vaccination was associated with improved PFS and OS in stage IV NSCLC receiving first-line ICI therapy, with a dose-related pattern. The association was attenuated after adjustment for tumor biology and is hypothesis-generating. These findings support the safety and potential clinical relevance of vaccination in this population and underline the need for structured monitoring during immunotherapy. Prospective validation is required.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.